Diabetes medications, specifically sodium-glucose cotransporter-2 (SGLT2) inhibitors, may be linked to a decreased risk of ...

Reduced risk for Alzheimer disease, vascular dementia, and Parkinson disease seen with SGLT2i use in type 2 diabetes. (HealthDay News) — For patients with type 2 diabetes, sodium-glucose cotransporter ...

First Amendment: Congress shall make no law respecting an establishment of religion, or prohibiting the free exercise thereof; or abridging the freedom of speech, or of the press; or the right of the ...

A specific class of diabetes drug appears to lower people's risk for dementia and Parkinson's disease, a new study shows.

Researchers have found that people who take a type of type 2 diabetes drugs SGLT2 inhibitors have a significantly lower risk ...

Sodium-glucose cotransporter-2 (SGLT2) inhibitors, a class of diabetes drugs also known as gliflozins, could lower the risk ...

A class of drugs for diabetes may be associated with a lower risk of dementia and Parkinson's disease, according to a study ...

Scientists found a 22 percent lower risk of any dementia and Parkinson's among a group taking SGLT2 inhibitors for type 2 ...

A class of drugs for diabetes may be associated with a lower risk of dementia and Parkinson's disease, according to a study ...

According to a new study, certain diabetes medications may significantly reduce this risk. These drugs, called gliflozins or ...